REVIEW PAPER
Brain-derived neurotrophic factor in gastroenterology oncology – short review of current literature
 
More details
Hide details
1
Medical University, Warsaw, Poland
CORRESPONDING AUTHOR
Tomasz Antoni Guzel   

Warszawski Uniwersytet Medyczny, ul.Banacha 1A, 02-097, Warszawa, Poland
 
 
KEYWORDS
TOPICS
ABSTRACT
Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophins group which plays a crucial role in brain development and neurogenesis. In the hypothalamus it is described as playing a role in energy metabolism and feeding behaviour. The hippocampal concentration of BDNF is believed to play an important role in learning and memory, it has a protective role in neurodegeneration and stress responses. BDNF is also known to take part in many other processes, e.g. angiogenesis, proliferation, cell migration and apoptosis. With its receptor TrkB, neurotrophins are important agents that playa role in neural diseases, as well as in cardiovascular and metabolic disorders, such as diabetes mellitus or acute coronary syndrome. Over the last few years, BDNF interaction with TrkB has also been found to be involved in cancer development, including brain, breast, urinary and gastrointestinal cancer. TrkB expression itself has been described as an aggressive neural tumour. BDNF/TrkB signalling takes part in promoting tumour growth and metastasis. The presented review focuses on gastrointestinal cancer and presents the current literature concerning influence of BDNF and TrkB receptor in cancer progression. Special attention is also paid to data confirming the possible role of BDNF/TrkB interaction in chemotherapy resistance. This might present the opportunity to assess the BDNF and TrkB pathway as a possible novel target for anticancer therapies.
 
REFERENCES (49)
1.
Roesler R. BDNF/TrkB signalin as an anti-tumor target. Expert Rev Anticancer Ther. 2011; 11(10): 1473–1475.
 
2.
Noble EE, Billington CJ, Kotz CM, Wang CF. The lighter side of BDNF. Am J Physiol Regul Integr Comp Physiol. 2011; 300(5): R1053-R1069.
 
3.
Bathina S, Das UN. Brain-derived neurotrophic factor and its clinical implications. Arch Med Sci. 2015; 11(6): 1164–1178.
 
4.
Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psych. 2008; 64: 527–32.
 
5.
Mirowska-Guzel D. The role of neurotrophic factors in the pathology and treatment of multiple sclerosis. Immunopharmacol Immunotoxicol. 2009; 31(1): 32–38.
 
6.
Laske C, Stransky E, Leyhe T, Eschweiler GW, Maetzler W, Wittorf A, et al. BDNF serum and CSF concentrations in Alzheimer’s disease, normal pressure hydrocephalus and healthy controls. J Psychiatr Res. 2007; 41(5): 387–94.
 
7.
Mirowska-Guzel D, Gromadzka G, Członkowski A, Członkowska A. BDNF -270 C>T polymorphisms might be associated with stroke type and BDNF -196 G>A corresponds to early neurological deficit in hemorrhagic stroke. J Neuroimmunol. 2012: 249(1–2): 71–75.
 
8.
Eyileten C, Kaplon-Cieslicka A, Mirowska-Guzel D, Malek L, Postula M. Antidiabetic effect of Brain-Derived Neurotrophic Factor and its association with inflammation in type 2 diabetes. J Diab Res. 2017; Article number 2823671.
 
9.
Eyileten-Postula C, Mirowska-Guzel D, Milanowski Ł, Zaremba M, Rosiak M, Cudna A, et al. Serum Brain-Derived Neurotrophic Factor is related to platelet reactivity and metformin treatment in adult patients with type 2 diabetes mellitus. Can J Diab. 2019; 43(10): 19–26.
 
10.
Pedersen BK. The diseasome of phycial inactivity – and the role of myokines in muscle-fat cross talk. J Physiol. 2009: 587(23): 5559–5568.
 
11.
Mirowska-Guzel D, Gromadzka G, Mendel T, Janus-Laszczuk B, Dzierka J, Sarzyńska- Długosz I, et al. Impact of BDNF -196 G>A and BDNF -270 C>T polymorphisms on stroke rehabilitation outcome: sex and age differences. Top Stroke Reh. 2014; 21(1): S33-S41.
 
12.
Cao L, Liu X, Lin EJ, Wang C, Choi EY, Riban V, et al. Environmental and genetic activation of a brain adipocyte bdnf/leptin axis causes cancer remission and inhibition. Cell. 2010; 142(1): 52–64.
 
13.
Linker RA, Lee DH, Flach AC, Litke C, van den Brandt J, Reichardt HM, et al. Thymocyte-derived bdnf influences t-cell maturation at the dn3/dn4 transition stage. Eur J Immunol. 2015; 45(5): 1326–1338.
 
14.
Jaboin J, Kim CJ, Kaplan DR, Thiele CJ. Brain-derived neurotrophic factor activation of trkb protects neuroblastoma cells from chemotherapy-nduced apoptosis via phosphatidylinositol 3-kinase pathway. Cancer Res. 2002; 62(22): 6756–6763.
 
15.
Li Z, Zhang J, Liu Z, Woo CW, Thiele CJ. Down-regulation of bim by brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from paclitaxel but not etoposide or cisplatin-induced cell death. Cell Death Differ. 2007; 14(2): 318–326.
 
16.
Radin D, LIppa A, Patel P, Leonardi D. Lifeguard inhibition of fas-mediated apoptosis: a possible mechanism for explaining the cisplatinresistance of triple-negative breast cancer cells. Biomed Pharmacother. 2016; 77: 161–166.
 
17.
Radin D, Patel P. BDNF: An oncogene or tumor suppressor? Anitcan Res. 2017; 37: 3983–3990.
 
18.
de Farias CB, Heinen TE, dos Santos RP, Abujamra AL, Schwartsmann, Roesler R. BDNF/TrkB signalling protects HT-29 human colon cancer cells from EGFR inhibition. Biochem Biophys Res Comm. 2012; 425: 328–332.
 
19.
Bao W, Qiu H, Yang T, Luo X, Zhang H, Wan X. Up-regulation of trkb promotes epithelial-mesenchymal transition and anoikis resistance in endometrial carcinoma. Plos One. 2013; 8(7): e70616.
 
20.
Yang X, Martin TA, Jiang WG. Biological Influence of brain-derived neurotrophic factor (BDNF) on colon cancer cells. Exp Ther Med. 2013; 6(6): 1475–1481.
 
21.
Han L, Zhang Z, Qin W, Sun W. Neurotrophic receptor TrkB: is it a predictor of poor prognosis for carcinoma patients? Med Hyp. 2007; 68: 407–409.
 
22.
Okugawa Y, Tanaka K, Inoue Y, Kawamura M, Kawamoto A, Hiro J, et al. Brain-derived neurotrophic factor/tropomyosin-related kinase B pathway in gastric cancer. Br J Canc. 2013; 108: 121–130.
 
23.
Bonavita E, Gentile S, Rubino M, Maina V, Papait R, Kunderfranco P, et al. PTX3 is an extrinsic oncosuppressor regulating complement-dependent inflammation in cancer. Cell. 2015; 160: 700–714.
 
24.
Choi B, Lee EJ, Shin MK, Park YS, Ryu MH, Kim SM, et al. Upregulation of brain-derived neurotrophic factor in advanced gastric cancer contributes to bone metastatic osteolysis by inducing long pentraxin 3. Oncotarget. 2016; 7(34): 55506–55517.
 
25.
Ai LS, Sun CY, Zhang L, Zhou SC, Chu ZB, Qin Y, et al. Inhibition of BDNF in multiple myeloma blocks osteoclastogenesis via down-regulated stroma-derived RANKL expression both in vitro and in vivo. PloS one. 2012; 7: e46287.
 
26.
Ai LS, Sun CY, Wang YD, Zhang L, Chu ZB, Qin Y, et al. Gene silencing of the BDNF/TrkB axis in multiple myeloma blocks bone destruction and tumor burden in vitro and in vivo. Int J Canc. 2013; 133: 1074–1084.
 
27.
Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology. 2001; 142: 5050–5055.
 
28.
Xu AJ, Fu LN, Wu HX, Yao XL, Meng R. MicroRNA-744 inhibits tumor cell proliferation and invasion of gastric cancer via targeting brain-derived neurotrophic factor. Mol Med Rep. 2017; 16: 5055–5061.
 
29.
Ding D, Hou R, Gao Y, Feng Y. miR-613 inhibits gastric cancer progression through repressing brain derived neurotrophic factor. Exp Therap Med. 2018; 15: 1735–1741.
 
30.
Cheng F, Yang Z, Huang F, Yin L, Yan G, Gong G. microRNA-107 inhibits gastric cancer cell proliferation and metastasis by targeting PI3K/AKT pathway. Mic Path. 2018; 121: 110–114.
 
31.
Esfandi F, Bouraghi H, Glassy MC, Taheri M, Kahaei MS, Oskooei VK, et al. Brain-derived neurotrophic factor downregulation in gastric cancer. J Cell Biochem. 2019; 1–7.
 
32.
Akil H, Perraud A, Melin C, Jauberteau MO, Mathonnet M. Fine-tuning of endogenous braiderived neurotrophic factor, TrkB and sortrilin in colorectal cancer cell survival. Plos One. 2011; 6(9): e25097.
 
33.
Akil H, Perraud A, Jauberteau MO, Mathonnet M. Tropomyosin-related kinase B/brain derived-neurotrophic factor signaling pathway as a potential therapeutic target for colorectal cancer. WJG. 2016; 22(2): 490–500.
 
34.
Tanka K, Okugawa Y, Toiyama Y, Inoue Y, Saigusa S, Kawamura M, et al. Brain-Derived Neurotrophic Factor (BDNF)-induced tropomyosin-related kinase B (Trk B) signaling is a potential therapeutic target for peritoneal carcinomatosis arising from colorectal cancer. Plos One. 2014; 9(5): e96410.
 
35.
Fan M, Sun J, Wang W, Fan J, Wang L, Zhang X, et al. Tropomiosin-related kinase B promotes distant metastasis of colorectal cancer through protein kinase B-mediated anoikis suppression and correlates with poor prognosis. Apoptosis. 2014; 19:860–870.
 
36.
Yu Y, Zhang S, Wang X, Yang Z, Ou G. Overexpression of TrkB promotes the progression of colon cancer. APMIS. 2010; 118: 188–195.
 
37.
Brierley GV, Priebe IK, Purins L, Fung KY, Tabor B, Lockett T, et al. Serum concentration of brain derived-neurotrophic factor (BDNF) are decreased in colorectal cancer patients. Cancer Biomark. 2013; 13(2): 67–73.
 
38.
Ketterer K, Rao S, Friess H, Weiss J, Buchler MW, Korc M. Reverse transcription-PCR analisys of laser-captured cell points to potential paracrine and autocrine actions of neurotrophins in pancreatic cacer. Clin Cancer Res. 2003; 9: 5127–5136.
 
39.
Miknyoczki SJ, Lang D, Huang L, Klein-Szanto AJ, Dionne CA, Rugerri BA. Neurotrophins and Trk receptors in human pancreatic ductal adenocarcinoma: expression patterns on in vitro invasive behavior. Int J Cancer. 1999; 81:417–427.
 
40.
Schneider MB, Standop J, Ulrich A, Wittel U, Friess H, Andren-Sanberg A, et al. Expression of nerve growth factors in pancreatic neural tissue and pancreatic cancer. J Histochem Cytochem. 2001; 49: 1205–1210.
 
41.
Sakamoto Y, Kitajima Y, Edakuni G, Sasatomi E, Mori M, Kitahara K, et al. Expression of Trk tyrosine kinase receptor is a biologic marker for cell proliferation and perineural invasion of human pancreatic ductal adenocarcinoma. Oncol Rep. 2001; 8: 477–484.
 
42.
Gasparini G, Pellegatta M, Crippa S, Lena MS, Belfiori G, Doglioni C, et al. Nerves and Pancreatic Cancer: New Insights into A Dangerous Relationship. 2019; 11: 893–919.
 
43.
Renz BW, Takahashi R, Tanaka T, Macchini M, Hayakawa Y, Dantes Z, et al. ß2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer. Cancer Cell. 2018; 33(1): 75–90.
 
44.
Johnson MD, Stone B, Thibodeau BJ, Baschnagel AM, Galoforo S, Fortier LE, et al. The significance of Trk receptors in pancreatic cancer. Tumor Biol. 2017; 1–13.
 
45.
Yang ZF, Ho DW, Lau CK, Tam KH, Lam CT, Yu WC, et al. Significance of the serum brain-derived neurotrophic factor and platelets in hepatocellular carcinoma. Oncol Rep. 2006; 16: 1237–1243.
 
46.
Yang ZF, Ho DW, Lam CT, Luk JM, Lum CT, Yu WC, et al. Identification of brain-derived neurotrophic factor as a novel functional protein in hepatocellular carcinoma. Cancer Res. 2005; 65(1): 219–225.
 
47.
Guo D, Hou X, Zhang H, Sun W, Zhan L, Liang J, et al. More expressions of BDNF and TrkB in multiple hepatocellular carcinoma and anti-BDNF or K252a induced apoptosis, suppressed invasion of HepG2 and HCCLM3 cells. J Exp Clin Cancer Res. 2011; 30(1): 97–105.
 
48.
Lam CT, Yang ZF, Chi-Keung, Lau CK, Tam KH, Fan ST, et al. Brain-Derived Neurotrophic Factor promotes tumorigenesis via Induction of neovascularization: implication in hepatocellular carcinoma. Clin Cancer Res. 2011; 17(10): 3123–3133.
 
49.
Long J, Jiang C, Liu B, Fang S, Kuang M. MicroRNA-15a-5p suppresses cancer proliferation and division in human hepatocellular carcinoma by targeting BDNF. Tumor Biol. 2016; 37: 5821–5828.
 
eISSN:1898-2263
ISSN:1232-1966